Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (95)

« Back to Publications

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study

Kone M. et al, (2025), The Lancet Infectious Diseases

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings

Bundi CK. et al, (2025)

Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons

Ogwang R. et al, (2025), Frontiers in Immunology, 16

Uncovering the genetic diversity of the malaria parasite antigen MSP2 across Sub-Saharan Africa

Zerebinski J. et al, (2025)

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Kibwana E. et al, (2025), Frontiers in Immunology, 16

Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial

Bundi C. et al, (2025), Frontiers in Immunology, 16

Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella

Randall AZ. et al, (2025), mSphere, 10

Reversible host cell surface remodelling limits immune recognition and maximizes survival of Plasmodium falciparum gametocytes

Ngotho P. et al, (2025), PLOS Pathogens, 21, e1013110 - e1013110

Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults

Kinyua AW. et al, (2024), Journal of Infection, 89, 106252 - 106252

R21/Matrix-M Protects Against Dermal but not Against Venous Parasites in Human Challenge Studies

Kapulu MC. et al, (2024)

Full-length MSP1 is a major target of protective immunity after controlled human malaria infection

Rosenkranz M. et al, (2024), Life Science Alliance, 7, e202301910 - e202301910

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge

Nkumama IN. et al, (2024), Immunity, 57, 1215 - 1224.e6

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

Sang S. et al, (2024)

Reversible host cell surface remodelling limits immune recognition and maximizes transmission of Plasmodium falciparum gametocytes

Ngotho P. et al, (2024)

Load More

1
2
3
4
5
6
7